Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Faron to Present at the Proactive Investors One2One Forum on 22 June 2016
TURKU - FINLAND 22 June 2016 - Faron Pharmaceuticals Ltd (LON: FARN), the clinical stage biopharmaceutical company, announces today that Markku Jalkanen, Chief Executive Officer, is scheduled to present at the Proactive Investors One2One Forum on Wednesday 22 June 2016 at 6:00pm in London.
The event will be held at Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB from 6:00pm to 8:00pm, followed by a drinks reception.
This event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.
Further information can found at: http://www.proactiveinvestors.co.uk/register/event_details/63
For more information, please contact:
Faron Pharmaceuticals Oy
Katja Wallenlind
Phone +358 (50) 577 4807
E-mail: katja.wallenlind@faronpharmaceuticals.com
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson and Rebecca Anderson
Phone: +44 207 148 7900
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Ltd
Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen®. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach called TIET (Tumour Immunity Enabling Technology). Faron Pharmaceuticals Ltd is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com
This information is provided by RNS